IMUNON (IMNN) announced that new translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of ...

The publication introduces a genetic identification system that enables plasmids to carry embedded documentation, improving traceability, verification, and secure exchange in biotech research and ...

Adeno-associated viral vectors (AAV vectors) are essential tools for delivering gene therapy to patients and are usually manufactured using plasmid-based approaches. However, there are challenges with ...

ZHENJIANG, China, Dec. 7, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio ...

Ardena Acquired Catalent’s Somerset, NJ, oral solids development and small-scale drug product manufacturing facility for an undisclosed price, in a deal completed in February. In Somerset, expanded ...

DUBLIN, Nov. 30, 2020 /PRNewswire/ -- The "CRISPR Technology Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

IMUNON announces promising Phase 1 results for IMNN-101, a DNA plasmid vaccine demonstrating enhanced durability and potential advantages over mRNA vaccines. Phase 1 clinical trial results of IMNN-101 ...

Scientists use plasmids as the leading gene delivery technology for a variety of research and clinical applications related to gene therapy. Traditional approaches to plasmid creation often result in ...

DNA plasmid technology has many applications. Inovio’s Covid-19 vaccine may still have a global market. Inovio potential HPV related therapies look headed for success. Glioblastoma therapy success is ...

SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', 688238.SH), a gene and cell therapy-focused contract research organization (CRO) and contract development and ...